Duke Comp Cancer Inst. Core Support Grant
Duke Comp Cancer Inst. Core Support Grant
批准号:
8322901
负责人:
ANTHONY MEANS
金额:
$7.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-01-01 至 2014-12-31
关键词:
American Cancer SocietyBasic ScienceBiomedical ResearchCancer BiologyCancer PatientChargeClinical OncologyCollaborationsDataDepartment of DefenseDevelopmentDevelopmental BiologyEnrollmentFundingFutureGenomicsGoalsGrantInstitutesInterdisciplinary StudyJournalsLaboratoriesMalignant NeoplasmsNational Cancer InstitutePaperPatientsPeer ReviewPilot ProjectsPubMedPublicationsPublishingRequest for ApplicationsResearchResearch InstituteResource SharingResourcesScientific Advances and AccomplishmentsSignal PathwaySocietiesSourceTestingTherapeutic Clinical Trialanticancer researchcancer riskchemotherapyimprovedinnovationinsightmemberoncologyoperationprogramsstatistical center
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The recently reorganized Duke Comprehensive Cancer Institute (DCCI) is charged to serve as the center of
all Duke activities in cancer, with an imperative to oversee all of the Duke cancer operations in the future. As
a matrix center in one of the largest biomedical research institutes, the DCCI has been continuously
supported by the National Cancer Institute (NCI) for over 36 years, by leveraging Duke's basic research
strengths with significant clinical oncology research excellence which is enabled by treating 5,581 new
cancer patients annually, enrolling over 1,000 patients annually onto therapeutic clinical trials, and enhanced
by the presence of national oncology research resources, such as the data and statistical centers of two
NCI-funded cooperative groups. Total membership in the DCCI is 285 members, with members having an
increasingly prominent focus in cancer research and increased amount of NCI funding since 2004. Total
funding for program members is $331,617,013, of which $269,525,804 is from peer-reviewed sources. A
cancer focus is illustrated by $77,785,582 or 23.5% of funding from the NCI, the American Cancer Society or
the Department of Defense. From 2004-2008, program members published 6,941 papers in peer-reviewed
journals cited in PubMed. Of these publications, 10% are the result of intra-programmatic collaborations and
19% due to inter-programmatic collaborations. In this competitive renewal application, we request support
our membership in 11 Research Programs supported by 17 Shared Resources. DCCI members made
significant scientific advances including: the development of innovative genomic tests to predict which cancer
patients would respond to specific chemotherapy, and basic insight into critical signaling pathways in cancer
and developmental biology. The DCCI oversees all cancer related philanthropy at Duke, and these funds
have been used to support recruitment of new members, innovative pilot projects, support of multidisciplinary
research, and new laboratory and administrative space. This application for ongoing support of
the DCC articulates the principles, goals and strategies for propelling the DCCI to fully leverage the
enormous advances in biomedical research at Duke and beyond, to improve and extend the lives of cancer
patients with cancer and at risk for cancer, and delivering these to society.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金